CN117751106A - 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 - Google Patents

作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 Download PDF

Info

Publication number
CN117751106A
CN117751106A CN202280040512.3A CN202280040512A CN117751106A CN 117751106 A CN117751106 A CN 117751106A CN 202280040512 A CN202280040512 A CN 202280040512A CN 117751106 A CN117751106 A CN 117751106A
Authority
CN
China
Prior art keywords
alkyl
substituted
ring
cycloalkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280040512.3A
Other languages
English (en)
Chinese (zh)
Inventor
H·张
P·陈
Z·蔡
姜飞
孙佩华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weijiu Biotechnology Suzhou Co ltd
Original Assignee
Weijiu Biotechnology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weijiu Biotechnology Suzhou Co ltd filed Critical Weijiu Biotechnology Suzhou Co ltd
Publication of CN117751106A publication Critical patent/CN117751106A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280040512.3A 2021-04-30 2022-04-28 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 Pending CN117751106A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/091510 2021-04-30
CN2021091510 2021-04-30
PCT/US2022/026832 WO2022232459A1 (en) 2021-04-30 2022-04-28 Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists

Publications (1)

Publication Number Publication Date
CN117751106A true CN117751106A (zh) 2024-03-22

Family

ID=81748636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280040512.3A Pending CN117751106A (zh) 2021-04-30 2022-04-28 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物

Country Status (10)

Country Link
US (1) US20250230140A1 (https=)
EP (1) EP4330249A1 (https=)
JP (1) JP2024517769A (https=)
KR (1) KR20240044386A (https=)
CN (1) CN117751106A (https=)
AU (1) AU2022264579A1 (https=)
CA (1) CA3218258A1 (https=)
IL (1) IL308035A (https=)
MX (1) MX2023012830A (https=)
WO (1) WO2022232459A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109878A1 (zh) * 2021-12-15 2023-06-22 武汉人福创新药物研发中心有限公司 三氮唑类lpar1拮抗剂及其用途
WO2025051267A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途
WO2025051266A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126084A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7208240B2 (ja) * 2017-12-19 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
WO2020257135A1 (en) * 2019-06-18 2020-12-24 Bristol-Myers Squibb Company Triazole carboxylic acids as lpa antagonists
WO2022034568A1 (en) * 2020-08-11 2022-02-17 Viva Star Biosciences Limited Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Also Published As

Publication number Publication date
WO2022232459A1 (en) 2022-11-03
KR20240044386A (ko) 2024-04-04
EP4330249A1 (en) 2024-03-06
CA3218258A1 (en) 2022-11-03
IL308035A (en) 2023-12-01
AU2022264579A1 (en) 2023-12-14
JP2024517769A (ja) 2024-04-23
US20250230140A1 (en) 2025-07-17
MX2023012830A (es) 2024-01-19

Similar Documents

Publication Publication Date Title
CN116669727B (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
AU2017281439B2 (en) Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
AU2015284135B2 (en) Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
EP3728222B1 (en) Cyclohexyl acid pyrazole azines as lpa antagonists
CN117751106A (zh) 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物
WO2019126103A1 (en) Cyclohexyl acid pyrazole azoles as lpa antagonists
EP4423068B1 (en) Rxfp1 agonists
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
AU2014234908A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
CN118251393A (zh) 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物
CN114761399B (zh) 作为布鲁顿酪氨酸激酶抑制剂的咪唑甲酰胺衍生物
HK40102702A (zh) 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物
US12338255B2 (en) Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40100136A (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
HK40116219A (zh) 新型双环经取代的磺酰脲化合物作为白介素-1活性的抑制剂
HK40107097A (zh) 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物
CN117659022A (zh) 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
HK40029777A (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
HK1216882B (en) Ship1 modulators and methods related thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102702

Country of ref document: HK